Alginor ASA
Alginor's green innovation, AORTA, increases the utilisation ratio of seaweeds from approximately 15 to 100% without using formaldehyde and other harmful chemicals.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | NOK400m | Late VC | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (1 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2232 %) | (2120 %) | (7650 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2425 %) | (2829 %) | (9735 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Manufacturer of kelp-based life science ingredients or pharmaceutical and nutraceutical applications based in Haugesund, Norway. . The company harvests and biorefins Laminaria Hyperborea to offer mannitol, fucoidan, cellulose, alginate, oligosaccharides, polyphenols, carotenoids, amino acids, savoury, laminarin, biobased materials and borea powder, enable companies to produce without downstream waste and zero formaldehyde.
Keywords: Pharmaceuticals and Biotechnology, Life Science, Life Science R&D, Nutraceutical Ingredients, Pharmaceutical Ingredients, Raw Material, Raw Materials.